Evidence map›Paper›PMID 41163682›Full record

ArticleFrontiers in endocrinology2025

First in class monoclonal antibody potentiating human follicle stimulating hormone activity improves spermatogenesis in azoospermic rodent models.

Elodie Kara, Jérémy Decourtye, Laurence Dupuy, Sophie Casteret, Philippe Bouchard, René Frydman, Marie-Christine Maurel

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elodie KaraIgyxos Biotherapeutics, Centre INRAE Val de Loire, Nouzilly, France.
Jérémy DecourtyeIgyxos Biotherapeutics, Centre INRAE Val de Loire, Nouzilly, France.
Laurence DupuyIgyxos Biotherapeutics, Centre INRAE Val de Loire, Nouzilly, France.
Sophie CasteretIgyxos Biotherapeutics, Centre INRAE Val de Loire, Nouzilly, France.
Philippe BouchardHôpital Foch, Service de Gynécologie Obstétrique, Suresnes, France.
René FrydmanHôpital Foch, Service de Gynécologie Obstétrique, Suresnes, France.
Marie-Christine MaurelIgyxos Biotherapeutics, Centre INRAE Val de Loire, Nouzilly, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: Potentiation of recombinant hFSH (rhFSH)-, human luteinizing hormone/chorionic gonadotropin (hLH/hCG)-, or human thyroid stimulating hormone (TSH)-mediated cyclic adenosine monophosphate (cAMP) induction Results: IGX12 dose-dependently potentiated rhFSH induction of cAMP production Conclusion: IGX12 is a first-in-class humanized monoclonal antibody (mAb) that potentiated FSH activity

Indexed as

Antibodies, MonoclonalAzoospermiaFollicle Stimulating Hormone, HumanSpermatogenesisAnimalsDisease Models, AnimalFemaleHEK293 CellsHumansMaleMiceRatsRats, Sprague-DawleyReceptors, FSHAntibodies, MonoclonalFollicle Stimulating Hormone, HumanReceptors, FSHantibodyazoospermiafertilityfollicle stimulating hormonespermatogenesis

Identifiers

PMID41163682
PMCPMC12558798

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.